George O'Leary - 22 Jul 2026 Form 4 Insider Report for HealthLynked Corp (HLYK)

Reporting relationship: Chief Financial Officer, Director
Issuer ticker: HLYK
Reported as of: 22 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Jul 2026, 16:09:18 UTC
Prior SEC filing: 19 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ George O'Leary

Key filing fact

George O'Leary filed Form 4 for HealthLynked Corp (HLYK) on 24 Jul 2026.

Key facts

This page summarizes George O'Leary's Form 4 filing for HealthLynked Corp (HLYK).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Jul 2026, 16:09.

Change

Previous filing in this sequence was filed on 19 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001430860 Primary reporting owner

O'Leary George

Relationship: Chief Financial Officer, Director
Address: 1265 CREEKSIDE PKWY, SUITE 200, NAPLES
Signature: /s/ George O'Leary
Signature date: 24 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

HLYK transaction Derivative

Options to purchase common stock

Award

Transaction value
Shares: +35,000
Change %: +1340%
Price: $0.000000^*
Shares after: 37,612
Date: 22 Jul 2026
Ownership: Direct
Underlying class: Common stock
Underlying amount: 35,000
Exercise price: $3.50
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Options vest in full upon the Issuer's successful approval for listing on the Nasdaq Capital Market while filer is actively serving as Interim Chief Financial Officer of the Issuer.

Footnote F2

Includes options being reported hereunder plus 2,612 warrants with an exercise price of $6.70.